Meet Kevin Wake, a 57-year-old sickle cell warrior from Kansas City, who shares his personal journey living with this lifelong genetic blood disorder.
In this emotional video, meet Kate Vander Weele who shares her family’s journey as her 12-year-old son Logan battles Duchenne muscular dystrophy, a rare and fatal genetic disease that causes progressive muscle loss.
On Sunday, November 9, Senate Majority Leader Thune announced that he had reached an agreement with a group of 8 Democratic senators and the White House on a deal to end the longest shutdown in U.S. history. On Monday, November 10, the Senate approved the government funding bill by a vote of 60-40, which sends the legislative package back to the House of Representatives.
To discuss managed care approaches to bsAbs with a focus on FL and DLBCL, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2025.
To discuss navigating the rapidly changing landscape of ER+/HER2− metastatic breast cancer (mBC), AMCP Market Insights virtually convened an expert panel of managed care stakeholders in February 2025.
On November 6, 2025, the Centers for Medicare & Medicaid Services (CMS) released the GENEROUS Model (Generating Cost Reductions for U.S. Medicaid Model). The model aims to achieve Most Favored Nation (MFN) international pricing for Covered Outpatient Drugs (CODs) while maintaining or improving the quality of care for Medicaid beneficiaries.
On November 6, 2025, the Centers for Medicare & Medicaid Services (CMS) released the GENEROUS Model (Generating Cost Reductions for U.S. Medicaid Model). The model aims to achieve Most Favored Nation (MFN) international pricing for Covered Outpatient Drugs (CODs) while maintaining or improving the quality of care for Medicaid beneficiaries.
President Donald Trump announced a series of agreements with Eli Lilly and Company and Novo Nordisk to offer Most-Favored-Nation (MFN) prices on two GLP-1 therapies, semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand names Mounjaro and Zepbound). This marks the fourth and fifth publicly announced agreements between the Trump administration and pharmaceutical manufacturers, joining earlier announcements with Pfizer, AstraZeneca, and EMD Serono. The manufacturers also agreed to cap prices for insulin products and other commonly prescribed diabetes medications.
On October 31, 2025, the Centers for Medicare and Medicaid Services (CMS) issued the Physician Fee Schedule final rule (Final Rule) to be published in the Federal Register on November 5, 2025.
AMCP Legislative & Regulatory Briefing — October 2025
